TNF-alfa İnhibitörleri ve Tüberküloz Riski
Yıl: 2017 Cilt: 11 Sayı: 2 Sayfa Aralığı: 82 - 86 Metin Dili: Türkçe DOI: 10.5578/ced.57496 İndeks Tarihi: 26-07-2019
TNF-alfa İnhibitörleri ve Tüberküloz Riski
Öz: Otoimmün hastalıkların tedavisinde tümör nekroz faktörü-alfa (TNF-) inhibitörlerinin kullanımı son yıllarda giderek artış göstermektedir. Kli- nikte en çok kullanılan TNF-inhibitörleri; etanersept, infliksimab ve adalimumabtır. TNF-; tüberküloz patogenezinde önemli yer tutan bir mediatör olduğundan, TNF-inhibitörlerinin kullanımının tüberküloz gelişim riskini artırması şaşırtıcı değildir. Bu risk TNF-inhibitörü ajanları içinde de farklılık göstermektedir. Bu nedenle TNF-inhibitörü kulla- nımı adayı olan hastalar tedavi öncesi ve sırasında tüberküloz gelişimi açısından yakın takip edilmelidir. Tarama için altı ayda bir ayrıntılı anam- nez, fizik muayene, tüberkülin deri testi ve/veya interferon gama (IFN-) salınım testi ile akciğer grafisi önerilmektedir.
Anahtar Kelime: Konular:
The Risk of Tuberculosis and TNF-alpha Inhibitors
Öz: The clinical use of TNF-alpha inhibitors have been increasing in the treatment of autoimmune disorders. The most common anti-TNF-alpha agents on clinical use are ethanercept, infliximab and adalimumab. TNF- alpha is an important mediator in the pathogenesis of tuberculosis, therefore the use of TNFAI increases the risk of tuberculosis. Patients who are on anti-TNF alpha treatment should be carefully evaluated for tuberculosis risk before and during therapy. The recommended screening tools are detailed history, physical examination, tuberculin skin test and/or interferon gamma (IFN-release assay and chest X-Ray every six months.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am 2010;24:285- 306. [CrossRef]
- Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9:164-72. [CrossRef]
- Toussi SS, Pan N, Walters HM, et al. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 2013;57:1318-30. [CrossRef]
- Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72. [CrossRef]
- Benini J, Ehlers EM, Ehlers S. Different types of pulmonary granuloma necrosis in immunocompetent vs. TNFRp55-gene-deficient mice aerogenically infected with highly virulent Mycobacterium avium. J Pathol 1999;189:127-37. [CrossRef]
- Bopst M, Garcia I, Guler R, et al. Differential effects of TNF and LTalpha in the host defense against M. bovis BCG. Eur J Immunol 2001;31:1935-43. [CrossRef]
- Randhawa PS. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 1990;22:153-5. [CrossRef]
- Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55. [CrossRef]
- Dorhoi A, Kaufmann SH. Tumor necrosis factor alpha in mycobacterial infection. Semin Immunol 2014;26:203-9. [CrossRef]
- Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5. [CrossRef]
- Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104. [CrossRef]
- Raval A, Akhavan-Toyserkani G, Brinker A, Avigan M. Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007;147:699-702. [CrossRef]
- Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8. [CrossRef]
- Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 2005;34:12-8. [CrossRef]
- Ringheanu M, Daum F, Markowitz J, et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn’s disease. Inflamm Bowel Dis 2004;10:801-10. [CrossRef]
- Saliu OY, Sofer C, Stein DS, et al. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006;194:486-92. [CrossRef]
- Nardell EA, Wallis RS. Here today--gone tomorrow: the case for transient acute tuberculosis infection. Am J Respir Crit Care Med 2006;174:734-5. [CrossRef]
- Coaccioli S, Di Cato L, Marioli D, et al. Impaired cutaneous cell-mediated immunity in newly diagnosed rheumatoid arthritis. Panminerva Med 2000;42:263-6. [CrossRef]
- Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004;53:683-6. [CrossRef]
- Keser G, Direskeneli H, Akkoç N, et al. TNF-α: Engelleyici ilaç kullanan olguların tedavi öncesinde tüberküloz açısından değerlendirilmesi ve alınması gerekli önlemler. RAED II. Uzlaşı Toplantısı Raporu, 7 Mayıs 2005, İzmir.
- Kıyan E. Bağışıklığı baskılanmış durumlarda tüberküloz: Tüberküloz. In: Özkara Ş, Kılıçaslan Z (editörler). İstanbul: Aves Yayıncılık, 2010:383-98.
- Garcia Vidal C, Rodríguez Fernández S, Martínez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005;40:756-9. [CrossRef] Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life- threatening tuberculosis. Clin Infect Dis 2009;48:1429-32. [CrossRef]
- Rivoisy C, Nicolas N, Mariette X, et al. Clinical features and risk factors of paradoxical aggravation of tuberculosis after anti-TNF-alpha withdrawal. A case-control study. European Society of Clinical Microbiology and Infectious Diseases 2012. Oral presentation O227.
| APA | ACAR M, SÜTÇÜ M, SALMAN N, SOMER A (2017). TNF-alfa İnhibitörleri ve Tüberküloz Riski. , 82 - 86. 10.5578/ced.57496 |
| Chicago | ACAR Manolya,SÜTÇÜ Murat,SALMAN Nuran,SOMER Ayper TNF-alfa İnhibitörleri ve Tüberküloz Riski. (2017): 82 - 86. 10.5578/ced.57496 |
| MLA | ACAR Manolya,SÜTÇÜ Murat,SALMAN Nuran,SOMER Ayper TNF-alfa İnhibitörleri ve Tüberküloz Riski. , 2017, ss.82 - 86. 10.5578/ced.57496 |
| AMA | ACAR M,SÜTÇÜ M,SALMAN N,SOMER A TNF-alfa İnhibitörleri ve Tüberküloz Riski. . 2017; 82 - 86. 10.5578/ced.57496 |
| Vancouver | ACAR M,SÜTÇÜ M,SALMAN N,SOMER A TNF-alfa İnhibitörleri ve Tüberküloz Riski. . 2017; 82 - 86. 10.5578/ced.57496 |
| IEEE | ACAR M,SÜTÇÜ M,SALMAN N,SOMER A "TNF-alfa İnhibitörleri ve Tüberküloz Riski." , ss.82 - 86, 2017. 10.5578/ced.57496 |
| ISNAD | ACAR, Manolya vd. "TNF-alfa İnhibitörleri ve Tüberküloz Riski". (2017), 82-86. https://doi.org/10.5578/ced.57496 |
| APA | ACAR M, SÜTÇÜ M, SALMAN N, SOMER A (2017). TNF-alfa İnhibitörleri ve Tüberküloz Riski. Çocuk Enfeksiyon Dergisi, 11(2), 82 - 86. 10.5578/ced.57496 |
| Chicago | ACAR Manolya,SÜTÇÜ Murat,SALMAN Nuran,SOMER Ayper TNF-alfa İnhibitörleri ve Tüberküloz Riski. Çocuk Enfeksiyon Dergisi 11, no.2 (2017): 82 - 86. 10.5578/ced.57496 |
| MLA | ACAR Manolya,SÜTÇÜ Murat,SALMAN Nuran,SOMER Ayper TNF-alfa İnhibitörleri ve Tüberküloz Riski. Çocuk Enfeksiyon Dergisi, vol.11, no.2, 2017, ss.82 - 86. 10.5578/ced.57496 |
| AMA | ACAR M,SÜTÇÜ M,SALMAN N,SOMER A TNF-alfa İnhibitörleri ve Tüberküloz Riski. Çocuk Enfeksiyon Dergisi. 2017; 11(2): 82 - 86. 10.5578/ced.57496 |
| Vancouver | ACAR M,SÜTÇÜ M,SALMAN N,SOMER A TNF-alfa İnhibitörleri ve Tüberküloz Riski. Çocuk Enfeksiyon Dergisi. 2017; 11(2): 82 - 86. 10.5578/ced.57496 |
| IEEE | ACAR M,SÜTÇÜ M,SALMAN N,SOMER A "TNF-alfa İnhibitörleri ve Tüberküloz Riski." Çocuk Enfeksiyon Dergisi, 11, ss.82 - 86, 2017. 10.5578/ced.57496 |
| ISNAD | ACAR, Manolya vd. "TNF-alfa İnhibitörleri ve Tüberküloz Riski". Çocuk Enfeksiyon Dergisi 11/2 (2017), 82-86. https://doi.org/10.5578/ced.57496 |
